

• **Name:** Poh Tze Wei

• **Current Position:**

Regional Manager, Scientific and Product Marketing, Commercial Operations, Asia Pacific, Beckman Coulter Diagnostics

• **Country:** Singapore

**PROFESSIONAL APPOINTMENTS**

**Regional Manager, Scientific and Product Marketing**, Commercial Operations, Asia Pacific, Beckman Coulter Diagnostics. Present

**Scientific Marketing Manager**, Commercial Operations, Asia Pacific, Beckman Coulter Diagnostics. Sep 2018 – June 2021

- Scientific speaker at meetings and webinars for immunoassay and hematology portfolio
- Organize and support regional and local meetings and webinars
- Develop standard work for internal training of scientific key messages.
- Handling of scientific information requests across all products
- Management of clinical studies
- Review of scientific publications

**Medical Science Liaison, Gastroenterology**, Takeda Pharmaceuticals, Singapore. Aug 2016 – Sep 2018.

- Medical governance towards mitigation of potential compliance risks
- Medical and product training for local and regional cross function teams
- Regional and local advisory board planning and execution
- Medical planning and implementation of medical strategies
- Provide local medical support for formulary listing and regional clinical studies
- Handling of medical information requests (gastroenterology and anti-infectives)
- Deputy drug safety officer, pharmacovigilance.

**Research scientist**, Kyowa Hakko Kirin, Singapore. Jan 2014 – Aug 2016

- Evaluation of new technology and research opportunities in immuno-oncology.
- Attended oncology scientific meetings for updating of local and global teams.
- Immunology and oncology R&D center set up and implementation of SOPs.

**Senior research fellow**, Mayo Clinic, Scottsdale, Arizona, USA. Oct 2006 – Aug 2013

- Keystone Symposia Future of Science Fund scholarship, 2012
- Immunology, Transplantation & Infectious Disease Theme Fellowship, Mayo Clinic, 2008 – 2010
- Pre-clinical and clinical studies on:

- Effect of anti-TNFs on the immune system during IBD
- Role of myeloid derived suppressor cells in IBD and cancer
- Effect of Mucin 1 on the immune system in cancer

## **EDUCATION**

National University of Singapore, Singapore. Ph.D in Physiology, Apr 2007

- Graduate Research Scholarship, Department of Physiology, 2002 - 2006

National University of Singapore, Singapore. Bachelor of Science in Biomedical Science and Physiology (with honors), Aug 1998 – Aug 2002

## **PUBLICATIONS**

Osanai-Sasakawa A, Hosomi K, Sumitomo Y, Takizawa T, Tomura-Suruki S, Imaizumi M, Kasai N, **Poh T.W.**, Yamano K, Yong WP, Kono K, Nakamura S, Ishii T, Nakai R. An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models. *Am J Cancer Res.* 2018 Aug 1;8(8):1499-1513.

Kasai N, Sasakawa A, Hosomi K, **Poh T.W.**, Chua BL, Yong WP, So J, Chan SL, Soong R, Kono K, Ishii T, Yamano K. Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer. *Am J Transl Res.* 2017 Jul 15;9(7):3399-3410.

**Poh T.W.**, Gendler SJ. Clinical significance of beta-catenin in immunological disease and dysfunction: signaling and therapy. *Beta-Catenin: Structure, Function and Clinical Significance.* 2013 Nova Publishers, USA.

**Poh T.W.**, Gendler SJ. “Signaling from membrane mucins” *Mucins and cancer.* 2013 Future Science Group, UK.

**Poh T.W.**, Madsen C.S., Gorman J.E., Marler R.J., Leighton J.A., Cohen P.A. and Gendler S.J. “Down-regulation of hematopoietic MUC1 during colitis in mice is indicative of an increase in tumor promoting CD11b<sup>+</sup>Gr1<sup>+</sup> myeloid-derived suppressor cells” *Clinical Cancer Research,* 2013, Sep 15;19(18):5039-52.

**Poh T.W.**, Bradley J.M., Mukherjee P. and Gendler S.J. “Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b<sup>+</sup>Gr1<sup>+</sup> myeloid-derived suppressor cells from the bone marrow.” *Cancer Res.* 2009 Apr 15;69(8):3554-62.

**Poh T.W.**, Huang S, Hirpara JL, Pervaiz S. “LY303511 Amplifies TRAIL-induced Apoptosis in Tumor Cells by Enhancing DR5 Oligomerization, DISC Assembly, and Mitochondrial Permeabilization” *Cell Death Differ.* 2007 Oct; 14(10):1813-25.

